Wall Street brokerages forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will announce $27.71 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Spark Therapeutics’ earnings, with the highest sales estimate coming in at $28.50 million and the lowest estimate coming in at $26.92 million. Spark Therapeutics reported sales of $25.19 million during the same quarter last year, which would suggest a positive year over year growth rate of 10%. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 20th.

On average, analysts expect that Spark Therapeutics will report full year sales of $119.12 million for the current year, with estimates ranging from $72.80 million to $157.06 million. For the next year, analysts expect that the firm will post sales of $139.14 million, with estimates ranging from $137.00 million to $141.27 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Spark Therapeutics.

A number of research firms have commented on ONCE. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Mizuho reissued a “hold” rating and issued a $114.50 price target on shares of Spark Therapeutics in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Spark Therapeutics has a consensus rating of “Hold” and a consensus target price of $87.92.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Chicago Capital Management LLC bought a new stake in Spark Therapeutics during the 1st quarter valued at $11,481,000. Gabelli Funds LLC raised its holdings in Spark Therapeutics by 5.1% during the 2nd quarter. Gabelli Funds LLC now owns 622,467 shares of the biotechnology company’s stock valued at $63,728,000 after buying an additional 30,329 shares during the last quarter. California Public Employees Retirement System raised its holdings in Spark Therapeutics by 21.0% during the 1st quarter. California Public Employees Retirement System now owns 60,382 shares of the biotechnology company’s stock valued at $6,876,000 after buying an additional 10,482 shares during the last quarter. Havens Advisors LLC raised its holdings in Spark Therapeutics by 114.8% during the 2nd quarter. Havens Advisors LLC now owns 53,700 shares of the biotechnology company’s stock valued at $5,498,000 after buying an additional 28,700 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Spark Therapeutics by 6,497.2% during the 1st quarter. SG Americas Securities LLC now owns 317,060 shares of the biotechnology company’s stock valued at $36,107,000 after buying an additional 312,254 shares during the last quarter. Hedge funds and other institutional investors own 81.40% of the company’s stock.

ONCE stock traded down $0.10 during midday trading on Friday, reaching $100.92. The company had a trading volume of 1,857 shares, compared to its average volume of 306,681. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.56 and a quick ratio of 5.22. Spark Therapeutics has a 1 year low of $34.53 and a 1 year high of $114.20. The company has a market capitalization of $3.89 billion, a P/E ratio of -47.92 and a beta of 2.07. The firm has a 50-day moving average price of $99.59 and a 200-day moving average price of $99.52.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

See Also: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.